US 11654157
Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation
granted A61KA61K2121/00A61K31/513
Quick answer
US patent 11654157 (Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation) held by Shuttle Pharmaceuticals, Inc. expires Mon May 18 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Shuttle Pharmaceuticals, Inc.
- Grant date
- Tue May 23 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 18 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 10
- CPC classes
- A61K, A61K2121/00, A61K31/513, A61K31/7072, A61K33/243